PIK3CA and non-small cell lung carcinoma: In a study, approximately 14.9% of advanced NSCLC patients with EGFR mutations progressed under TKI treatment and developed resistance by acquiring at least one additional genetic mutation in the PI3K pathway, such as PIK3CA, PTEN, and AKT1 [100].